ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why STAAR Surgical (STAA) Stock Is Trading Lower Today

STAA Cover Image

What Happened?

Shares of medical lens company STAAR Surgical (NASDAQ: STAA) fell 3.5% in the afternoon session after the company announced a leadership transition, appointing interim co-CEOs following the recent resignation of its chief executive, which created uncertainty. 

The board appointed President and Chief Operating Officer Warren Foust and Chief Financial Officer Deborah Andrews to lead the company on an interim basis. This change followed the departure of CEO Stephen C. Farrell. The transition came during a turbulent period for the company, as investors had rejected a takeover deal just weeks prior to the CEO's resignation. The company's board has started a global search for a permanent chief executive to navigate its future.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy STAAR Surgical? Access our full analysis report here, it’s free.

What Is The Market Telling Us

STAAR Surgical’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 6 months ago when the stock gained 45.6% on the news that eye-care company Alcon announced a definitive agreement to acquire the company in an all-cash deal valued at approximately $1.5 billion. Under the terms of the deal, Alcon paid $28 in cash for each share of STAAR Surgical. This price marked a 51% premium to the company's closing stock price on the previous day. STAAR Surgical manufactured implantable lenses for vision correction, including its EVO family of Implantable Collamer® Lenses. The acquisition allowed Alcon to absorb a key player in the ophthalmic surgery space.

STAAR Surgical is down 22.8% since the beginning of the year, and at $18.22 per share, it is trading 36.2% below its 52-week high of $28.57 from August 2025. Investors who bought $1,000 worth of STAAR Surgical’s shares 5 years ago would now be looking at an investment worth $166.27.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.29
-0.09 (-0.04%)
AAPL  258.01
-2.47 (-0.95%)
AMD  246.78
+1.74 (0.71%)
BAC  53.06
+0.52 (1.00%)
GOOG  318.18
+2.46 (0.78%)
META  632.13
+2.27 (0.36%)
MSFT  381.83
+10.96 (2.96%)
NVDA  188.75
+0.12 (0.06%)
ORCL  153.92
+15.83 (11.46%)
TSLA  351.10
+2.15 (0.62%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.